Early PSA response correlates with better outcomes in mHSPC patients receiving ADT and ARPIs.

Citius Pharma re-submits its LYMPHIR™ BLA, comprising Denileukin Diftitox, aiming to treat relapsed/refractory Cutaneous T-Cell Lymphoma in adults.

Mupirocin (BACTROBAN) is an antibiotic that blocks RNA synthetase and treats impetigo from Staph aureus and Streptococcus pyogenes when applied to the skin.

Kurome Therapeutics has received authorization from the FDA to conduct clinical trials for KME-0584, aimed at addressing Acute Myeloid Leukemia (AML) and advanced-stage Myelodysplastic Syndromes (MDS).

Quetiapine, marketed as SEROQUEL, is an atypical antipsychotic medication developed and produced by AstraZeneca.

Acousia Therapeutics disclosed that it has initiated participant enrollment for its second stage PROHEAR trial.

Methotrexate, a DHFR-inhibiting drug approved in the US since 1953, is known for treating various conditions such as acute lymphoblastic leukemia, breast cancer, severe psoriasis, and rheumatoid arthritis in both adults and children.

Curadev proudly launches CRD3874, an innovative allosteric small molecule that uniquely activates the STING pathway without targeting the cGAMP site.

Pregabalin, commonly referred to as Lyrica®, is a well-known anticonvulsant medication, which has found its footing in the treatment of various medical conditions.

Repare Therapeutics Inc. announced the first patient has been treated in their LIONS Phase 1 trial, focusing on RP-1664 – a leading oral inhibitor targeting polo-like kinase 4, intended for solo therapy.

Topiramate, marketed under the trade name Topamax ®, is an anticonvulsant drug that was first approved in 1995 in the UK by Janssen Services.

Nuvig Therapeutics, Inc., initiates first human trial of NVG-2089 for treating inflammatory myopathies and severe autoimmune skin diseases.